BackKaryopharm Therapeutics Overview
Karyopharm Therapeutics Inc

Karyopharm Therapeutics Target Price

Where could KPTI trade next? Consensus target price: $7.3.

Get informed when a big investor buys or sells

+ Follow

Share Price

$1.82

Average Target Price

$7.33302.9% upside

3 analysts in the last 4 months

High: $16 | Low: $3

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-31H.C. WainwrightRobert Burns$364.8% upsideOpen
2026-07-31Robert W. Baird$364.8% upsideOpen
2026-07-21RBC CapitalBrian Abrahams$16779.1% upsideOpen
2026-05-06H.C. Wainwright$13614.3% upsideOpen
2026-04-27Piper Sandler$16779.1% upsideOpen
2026-03-09UBS$281438.5% upsideOpen
2025-12-17Goldman Sachs$12559.3% upsideOpen
2025-12-17Piper Sandler$12559.3% upsideOpen
2025-11-04RBC CapitalBrian Abrahams$19944% upsideOpen
2025-10-13H.C. WainwrightRobert Burns$15724.2% upsideOpen
2025-10-09Robert W. Baird$211053.8% upsideOpen
2025-10-08Leerink Partners$6229.7% upsideOpen
2024-06-10RBC CapitalBrian Abrahams$364.8% upsideOpen
2023-01-10Leerink Partners$5174.7% upsideOpen
2022-08-23Robert W. BairdCollen Kusy$14669.2% upsideOpen
2022-03-10RBC CapitalBrian Abrahams$8339.6% upsideOpen

Karyopharm Therapeutics (KPTI) FAQ

Karyopharm Therapeutics (KPTI) currently reports a target price of $7.3. Use the charts on this page to explore Karyopharm Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Karyopharm Therapeutics is $7.3, about 302.9% upside from the current share price of $1.82. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $7.3, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Karyopharm Therapeutics, and consider following KPTI for alerts when major investors trade the stock.

Karyopharm Therapeutics is classified in the Healthcare sector. On target price, it currently shows $7.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KPTI with unrelated industries.